Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty Drugsmeridian Casgevy coverage & Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentmeridianPolicy MDN.CP.PHAR.603

    Exagamglogene autotemcel (Casgevy) gene therapy coverage

    Customize your policy alerts

    Sign up for meridian Policy MDN.CP.PHAR.603 alerts

    Get alerted when Policy MDN.CP.PHAR.603 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Meridian Health Plan medical necessity and authorization criteria for Casgevy (exagamglogene autotemcel) for patients with sickle cell disease or transfusion-dependent β-thalassemia, including required documentation and committee review. Affects providers submitting prior authorization for Medicaid line of business.

    Policy Summary
    Payermeridian
    PolicyExagamglogene autotemcel (Casgevy) gene therapy coverage
    Policy CodePolicy MDN.CP.PHAR.603
    Change TypeNo material changes
    Effective DateJan 1, 2026
    Next Review Date
    Key ActionProvider must submit documentation (office notes, labs, or other clinical information) demonstrating that the member meets all approval criteria and requests require PDAC Utilization Management Review per CC.PHAR.21.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≥ 12 yrsminimum patient age
    ≥ 3 x10^6 CD34+/kgminimum cell dose
    One-timeone-time infusion
    12 monthsSCD approval duration

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    J3392HCPCS referenced

    Coverage Criteria

    Initial Therapy — Sickle Cell Disease

    Covered when ALL of the following are met:

    SCD initial criteria: 1. Diagnosis of sickle cell disease (SCD). 2. Confirmatory genetic testing. 3. Age ≥ 12 years at time of gene therapy administration. 4. Experienced recurrent VOCs (≥ 2 documented VOCs per year in the previous 24 months, based on provider attestation). 5. Provider attestation that participant is clinically stable and eligible to undergo hematopoietic stem cell transplantation (HSCT). 6. Documented trial and failure, contraindication, or intolerance to hydroxyurea. 7. Medication prescribed by or in consultation with a board-certified hematologist or transplant specialist experienced in SCD. 8. Dose contains a minimum of 3 x 10^6 CD34+ cells/kg;

    Initial Therapy — Transfusion-Dependent β-Thalassemia (TDT)

    Covered when ALL of the following are met:

    TDT initial criteria: 1. Diagnosis of transfusion-dependent β-thalassemia (TDT) with genetic confirmation. 2. Prescribed by or in consultation with a hematologist and transplant specialist. 3. Age ≥ 12 years. 4. Documentation of one of the following for the prior two years: (a) receipt of ≥ 100 mL/kg or ≥ 10 units pRBC per year, OR (b) receipt of ≥ 8 transfusions of pRBC per year. 5. Attestation from transplant specialist that member understands risks/benefits of alternative therapeutic options (e.g., allogeneic HSCT) and is clinically stable and eligible to undergo myeloablative conditioning and HSCT. 6. Member does not have any of the following: associated α-thalassemia with >1 alpha chain deletion, alpha multiplications, or associated sickle cell β-thalassemia. 7. Member has not received prior allogeneic HSCT. 8. Member has not received prior gene therapy. 9. Documentation within the last 6 months negative for active HIV, hepatitis B, and hepatitis C. 10. Member does not have advanced liver disease. 11. Member does not have current malignancy or immunodeficiency disorder. 12. Documentation of member's body weight in kg. 13. Dose contains a minimum of 3 x 10^6 CD34+ cells/kg;

    Non–FDA approved indications not specifically addressed in this policy are not authorized unless the provider supplies sufficient supporting documentation consistent with the plan's off‑label use requirements (see policy CP.PMN.53 and related evidence of coverage guidance).

    The inclusion or exclusion of any procedure or diagnosis code in this policy does not guarantee coverage. Providers must follow applicable plan coverage rules, current coding guidance, and submit claims using the most up‑to‑date code sets and professional coding resources.

    Casgevy (exagamglogene autotemcel) is authorized as a one‑time administration only; continued therapy or repeat dosing will not be authorized.

    Initial Therapy

    Initial therapy — Initial authorization granted when all specific indication criteria are met

    Initial authorization is granted when ALL specific indication criteria are met (see indication-specific criteria below).

    Initial therapy general: 1. Request must meet all applicable disease-specific initial approval criteria for SCD or TDT. 2. Prior authorization and supporting clinical documentation must be submitted for review; requests require PDAC Utilization Management review per plan procedures. 3. Approval is for a one-time infusion per lifetime; authorization duration (when applicable) is as specified in indication criteria (e.g., 12 months for SCD initial authorization).

    Dosing and product availability — Dosing and product availability details

    Dosing and product availability details:

    Dosing and product: Minimum recommended dose: 3 x 10^6 CD34+ cells/kg IV. Maximum dose: not applicable. Product is supplied as a single-dose cell suspension available in up to nine vials, each vial containing approximately 4 to 13 x 10^6 CD34+ cells/mL suspended in 1.5 to 20 mL cryopreservative medium.

    Continuation Criteria

    Continuation — All Indications

    All Indications

    Continuation therapy: Continued therapy is not applicable — Casgevy is indicated as a one-time administration and continued therapy will not be authorized.

    Coding and Code-based Criteria

    Referenced HCPCS CodeHCPCS
    J3392Injection, exagamglogene autotemcel, per treatment
    inv-07: Recurrent VOCs — ≥ 2 documented VOCs per year in previous 24 months
    Recurrent VOC threshold≥ 2 documented vaso-occlusive crises (VOCs) per year in the previous 24 months (based on provider attestation)
    Documentation requirementProvider attestation required to confirm frequency of VOCs
    Applicable indicationCriterion for Sickle Cell Disease initial authorization (age ≥ 12 years required)
    inv-08: Transfusion burden for TDT (option a) — ≥ 100 mL/kg or ≥ 10 units pRBC per year for previous 2 years
    Transfusion burden (option a)Receipt of ≥ 100 mL/kg or ≥ 10 units of pRBC per year for the previous 2 years
    Conversion guidance1 RBC unit ≈ 200–350 mL; see Appendix D for converting transfused volume to units

    Definitions

    inv-21: VOC (vaso-occlusive crisis) — definition and recurrent VOC threshold
    VOC definitionAn acute painful vaso-occlusive episode used for eligibility determination
    Recurrent VOC thresholdDefined as ≥ 2 documented VOCs per year in the previous 24 months (provider attestation)
    Use in policyRequired for SCD initial authorization (age ≥ 12 years and other criteria also required)
    inv-22: pRBC unit conversion — 1 RBC unit approximated as 200–350 mL; conversion guidance
    pRBC unit approximationOne RBC unit refers to approximately 200–350 mL of packed red blood cells
    Conversion for ≥350 mL bagsDivide volume transfused by 350 mL to convert to units

    Provider Actions and Prior Authorization

    Prior Authorization

    PDAC utilization management review required

    All requests reviewed under this policy require Precision Drug Action Committee (PDAC) Utilization Management Review; prior authorization and supporting clinical documentation must be submitted per CC.PHAR.21.

    • Refer to CC.PHAR.21 for PDAC process details.
    Prior Authorization

    Prior authorization required for HCPCS J3392

    Prior authorization is implied by inclusion of HCPCS code J3392 (Injection, exagamglogene autotemcel, per treatment); providers must follow the plan’s prior authorization submission processes for this code.

    • HCPCS J3392 is referenced in the policy coding implications.

    Site of Care and Specialist Requirements

    Note

    Specialist prescribing and transplant involvement required

    Therapy must be prescribed by or in consultation with hematology and transplant specialists experienced in sickle cell disease or transfusion‑dependent β‑thalassemia; transplant specialist involvement and assessment of transplant eligibility is required as part of the criteria.

    • Medication prescribed by or in consultation with a board‑certified hematologist or transplant specialist (SCD criteria)
    • Prescribed by or in consultation with a hematologist and transplant specialist and transplant attestation (TDT criteria)
    Note

    No site‑of‑care restrictions stated

    No site‑of‑care restrictions are specified in this portion of the document.

    Quantity Limits

    inv-27: Single administration — one-time infusion per lifetime
    Administration frequencySingle administration — one-time infusion per lifetime
    Quantity limit contextPolicy limits Casgevy to one course/infusion per member (one-time administration)
    Continuation policyContinued therapy is not authorized; therapy is a single administration
    inv-28: Up to nine vials per single-dose cell suspension
    Maximum vials per suspensionUp to nine vials per single-dose cell suspension
    Vial content rangeEach vial contains 4 to 13 x 10^6 CD34+ cells/mL in 1.5 to 20 mL cryopreservative

    Background

    Exagamglogene autotemcel (Casgevy) is an autologous CD34+ hematopoietic stem and progenitor cell–based gene therapy approved for patients aged ≥ 12 years with either sickle cell disease with recurrent vaso‑occlusive crises or transfusion‑dependent β‑thalassemia. Treatment requires confirmatory genetic testing, transplant eligibility assessment, and a minimum harvested dose of ≥ 3 x 10^6 CD34+ cells/kg. The product is supplied as a single‑dose cell suspension and may be provided in up to nine vials for the single infusion; dosing and safety details are described in the Casgevy Prescribing Information (Jan 2024) and supporting clinical references.

    Policy Summary
    Payermeridian
    PolicyExagamglogene autotemcel (Casgevy) gene therapy coverage
    Policy CodePolicy MDN.CP.PHAR.603
    Change TypeNo material changes
    Effective DateJan 1, 2026
    Next Review Date
    Key ActionProvider must submit documentation (office notes, labs, or other clinical information) demonstrating that the member meets all approval criteria and requests require PDAC Utilization Management Review per CC.PHAR.21.
    SourceLink
    On This Page
    Coverage CriteriaInitial TherapyContinuation CriteriaCoding and Code-based CriteriaDefinitionsProvider Actions and Prior AuthorizationSite of Care and Specialist RequirementsQuantity LimitsBackground
    ContextOne of two alternative transfusion-history criteria for TDT initial authorization (age ≥ 12 years required)
    inv-09: Transfusion burden for TDT (option b) — ≥ 8 transfusions of pRBC per year for previous 2 years
    Transfusion burden (option b)Receipt of ≥ 8 transfusions of pRBC per year for the previous 2 years
    ContextAlternative to volume/units threshold for TDT initial authorization (age ≥ 12 years required)
    Documentation periodPrevious 2 years (per policy criteria)
    inv-10: Minimum CD34+ cell dose — ≥ 3 x 10^6 CD34+ cells/kg
    Minimum CD34+ cell dose≥ 3 x 10^6 CD34+ cells/kg of body weight IV
    Dose typeMinimum recommended dose for both SCD and TDT indications
    Max doseNot applicable per policy (maximum dose not specified)
    inv-11: Minimum cell dose — 3 x 10^6 CD34+ cells/kg
    Minimum cell dose (alternate wording)3 x 10^6 CD34+ cells/kg
    Administration routeIntravenous (IV) administration per dosing section
    Applies toRequired element for initial authorization in both SCD and TDT criteria
    Conversion for <200 mL bagsDivide volume transfused by 200 mL to convert to units
    inv-23: Minimum recommended dose and product vial details — 3 x 10^6 CD34+ cells/kg; product supply details
    Minimum recommended dose3 x 10^6 CD34+ cells/kg IV (minimum)
    Product supply detailsSingle-dose cell suspension supplied in up to nine vials; each vial contains 4 to 13 x 10^6 CD34+ cells/mL in 1.5 to 20 mL cryopreservative medium
    Dose applicabilityDose specification applies to both SCD and TDT initial authorization requirements
    Step Therapy

    Step therapy: not applicable (authorization based on criteria)

    Step therapy is not applicable as authorization is contingent on meeting the listed indication-specific criteria (e.g., documented trial/failure/intolerance to hydroxyurea for SCD or required transfusion history for TDT).

    • Authorization requires meeting the coverage criteria rather than prior step therapy sequences.
    Step Therapy

    No step therapy rules stated

    The policy does not specify any step therapy rules in this section.

    Documentation Required

    Submit complete supporting clinical documentation

    Providers must submit documentation (office chart notes, lab results, or other clinical information) demonstrating the member meets all approval criteria, including confirmatory genetic testing, VOC/transfusion history, transplant eligibility attestation, hydroxyurea trial/failure/intolerance (if applicable), body weight when required, and minimum harvested cell dose.

    • Documentation of negative HIV, hepatitis B and C within last 6 months is required for TDT.
    • Include provider attestation of clinical stability and HSCT eligibility.
    • Document minimum CD34+ cell dose (≥ 3 x 10^6 cells/kg).
    Note

    Supporting references and plan notice

    Use the Casgevy Prescribing Information (Jan 2024) and the clinical literature cited in the policy (e.g., Frangoul et al., ClinicalTrials.gov listings, NHLBI guidance) to support clinical documentation; the plan reserves the right to change policy and providers must adhere to coverage terms, limitations, and applicable state Medicaid provisions.

    • Prescribing Information: Casgevy Prescribing Information. Boston, MA: Vertex Pharmaceuticals, Inc.; January 2024.
    • Cited literature and clinical trial references listed in policy Appendix/References should be included as supporting evidence.
    Denial Risk

    Documentation-based denials possible

    Requests that lack required documentation showing the member meets approval criteria, or requests for non–FDA‑approved indications without sufficient off‑label evidence per applicable off-label use policies, may be denied.

    • Non‑FDA indications require sufficient documentation per off‑label use policy CP.PMN.53 for Medicaid.
    Billing Rule

    Coding inclusion does not guarantee coverage/payment

    Inclusion of HCPCS J3392 or any other code in this policy is informational and does not guarantee coverage or payment; providers should reference current professional coding guidance before claim submission.

    • Codes referenced are for informational purposes only; inclusion/exclusion does not guarantee coverage.
    Product format
    Supplied as a single-dose cell suspension distributed across up to nine vials
    inv-23: Dosing specification — Minimum recommended dose and product vial content
    Minimum recommended dose (specification)Minimum recommended dose is 3 x 10^6 CD34+ cells/kg IV
    Product vial contentProduct supplied in up to nine vials, each containing 4 to 13 x 10^6 CD34+ cells/mL in 1.5 to 20 mL cryopreservative
    Administration formatSingle-dose cell suspension for one-time IV infusion